Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
Preprint
Abstract
Objective: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and widespread inflammation. Natural killer (NK) cells, essential for immune surveillance, exhibit profound dysfunction in SLE, including impaired cytotoxicity and cytokine production. However, the mechanisms underlying these abnormalities remain poorly understood. This study investigates how the accumulation of dysfunctional mitochondria due to defective mitophagy contributes to NK cell impairment in SLE and explores strategies to restore their function. Methods: Mitochondrial structure and function in NK cells from SLE patients (n=104) and healthy controls (n=104) were assessed using flow cytometry, transmission electron microscopy, and proteomics. Mitophagy-related gene expression was quantified by RT-qPCR. The effects of Urolithin A, a mitophagy activator, and hydroxychloroquine (HCQ) on mitochondrial recycling and NK cell function were evaluated in vitro . Results: SLE NK cells exhibited accumulation of enlarged, dysfunctional mitochondria, impaired lysosomal acidification, and increased cytosolic mitochondrial DNA leakage, consistent with defective mitophagy. Proteomic and transcriptional analyses revealed downregulation of key mitophagy-related genes. These abnormalities were associated with diminished NK cell effector functions, including reduced degranulation and cytokine production. In vitro , treatment with Urolithin A enhanced mitophagy, improved mitochondrial and lysosomal function, and restored NK cell effector responses. HCQ was also associated with partial recovery of mitochondrial recycling and NK cell function. Conclusion: These findings identify mitochondrial dysfunction and impaired mitophagy as major contributors to NK cell abnormalities in SLE. By uncovering a novel immunometabolic mechanism, this offers new insight into SLE pathogenesis and highlights potential therapeutic strategies targeting mitochondrial quality control.Keywords
This publication has 30 references indexed in Scilit:
- Assessing Mitochondrial DNA Release into the Cytosol and Subsequent Activation of Innate Immune‐related Pathways in Mammalian CellsCurrent Protocols, 2022
- Natural killer cells in inflammatory autoimmune diseasesClinical & Translational Immunology, 2021
- Metabolic regulation of organelle homeostasis in lupus T cellsClinical Immunology, 2012
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab studyArthritis & Rheumatism, 2012
- The role of B cells in lupus pathogenesisThe International Journal of Biochemistry & Cell Biology, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosusArthritis & Rheumatism, 2009
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982
- Cytotoxic antibodies to natural killer cells in systemic lupus erythematosusClinical Immunology and Immunopathology, 1982